[1] |
Freeman AG. Thyroid-associated eye disease. Lancet,1991,338:454-455.
|
[2] |
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.Trans Am Ophthalmol Soc,1994,92:477-588.
|
[3] |
许诺,黄丹平,宋亦悦,等. 甲状腺相关眼病患者眼表损害与相关因素分析. 中山大学学报•医学科学版,2010,31:833-837.
|
[4] |
黄筱敏,颜建华,刘敏. 甲状腺相关眼病患者的眼表功能分析. 中国实用眼科杂志,2010,12:1300-1304.
|
[5] |
Cawood TJ, Moriarty P, O'Farrelly C, et al. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab,2007,92:59-64.
|
[6] |
Ittermann T, Schmidt CO, Kramer A, et al. Smoking as a risk factor for thyroid volume progression and incident goiter in a region with improved iodine supply. Eur J Endocrinol,2008, 159:761-766.
|
[7] |
Rajendram R, Bunce C, Adams GG, et al. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology,2011,118:2493-2497.
|
[8] |
Bartley GB, Gorman CA. Diagnostic criteria for Graves′ ophthalmopathy. Am J Ophthalmol,1995,119:792-795.
|
[9] |
Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves′ ophthalmopathy. Clin Endocrinol(Oxf),1997,47:9-14.
|
[10] |
Van Dyk HJ. Orbital Graves′ disease. A modification of the “NO SPECS” classification. Ophthalmology,1981,88:479-483.
|
[11] |
Gatinel D. Double pass-technique limitations for evaluation of optical performance after diffractive IOL implantation. J Cataract Refract Surg,2011,37:621-622.
|
[12] |
Aldaba M, Vilaseca M, Diaz-Douton F, et al. Measuring the accommodative response with a double-pass system: comparison with the Hartmann-Shack technique. Vision Res,2012,62:26-34.
|
[13] |
Diaz-Douton F, Benito A, Pujol J, et al. Comparison of the retinal image quality with a Hartmann-Shack wavefront sensor and a double-pass instrument. Invest Ophthalmol Vis Sci,2006,47:1710-1716.
|
[14] |
Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol,2009,147:919-923.
|
[15] |
Villani E, Viola F, Sala R, et al. Corneal involvement in Graves′ orbitopathy: an in vivo confocal study. Invest Ophthalmol Vis Sci,2010,51:4574-4578.
|
[16] |
Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves′ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid,1997,7:885-889.
|
[17] |
Abraham-Nordling M, Wallin G, Traisk F, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol,2010,163:651-657.
|
[18] |
Ponto KA, Hommel G, Pitz S, et al. Quality of life in a german graves orbitopathy population. Am J Ophthalmol,2011, 152:483-490.
|
[19] |
Choi YJ, Lim HT, Lee SJ, et al. Assessing Graves′ ophthalmopathy-specific quality of life in Korean patients. Eye,2012,26:544-551.
|
[20] |
Karakaya A, Tuncel N, Alptuna G, et al. Influence of cigarette smoking on thyroid hormone levels. Hum Toxicol,1987,6:507-509.
|
[21] |
Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves′ orbitopathy (EUGOGO) on management of Graves′ orbitopathy. Thyroid,2008,18:333-346.
|